Please assess the completion status of the following clinical trial:

Trial Title: Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be able to give written consent~2. Men and women between 18 and 65 years of age who are recipients of a kidney transplant between 1 month and 5 years prior to the screening date~3. Subjects with at least one complaint of tremor and existence of postural tremor or action tremor on finger to nose as demonstrated by a score of at least 2 of any of the 4 upper extremity (UE) postural or action and intention assessments on the FTM clinical rating scale~4. Subjects experiencing symptomatic drug-induced hand tremor associated with use of Prograf or generic tacrolimus as demonstrated by responding no to each of the following question: Did you have a tremor that you noticed prior to starting Prograf or generic tacrolimus for your kidney transplant?, or Are you aware of a tremor that runs in your family?~5. Subjects taking a stable dose of oral Prograf or generic tacrolimus capsules for at least 7 days with trough levels of tacrolimus between 3 to 12 ng/mL. Subjects must maintain tacrolimus trough levels in this range during the 7 day Prograf or generic tacrolimus treatment phase (note that 1 dose adjustment at Study Day 3 \[a.m.dose\] is allowed for those subjects whose Day0/1 trough level is out of range.~6. Women of childbearing potential must have a negative serum pregnancy test within 7 days before study start.~Exclusion Criteria:~1. Recipients of any transplants including organ other than kidney and bone marrow~2. Subjects with an estimated glomerular filtration rate (eGFR) (MDRD7) \<30mL/min at Screening~3. Subjects incapable of understanding the purposed and risks of the study, who cannot give written informed consent and who are unwilling or unable to comply with study protocol requirements~4. Pregnant or nursing women~5. Subjects with reproductive potential who are unwilling/unable to use a double barrier method of contraception~6. Subjects who were treated with any other investigational agent within 3 months prior to screening~7. Subjects who are taking drugs that are likely to affect the PK levels of tacrolimus and are not on a stable dose of those medications (see Appendix 1)~8. Subjects who have essential tremor, Parkinsonism, or tremor from any cause other than tacrolimus-induced tremor;~9. Subjects who are taking or had been taking any drug within the past 30 days that is well known to promote tremors, including: amiodarone, beta-agonist inhalers (such as albuterol), cyclosporine, lithium, metoclopramide, theophylline, or valproate,or taking within the past 6 months the dopamine blocking agents (antipsychotics) (note, other such medication may be considered on a case-by-case basis at the discretion of the investigator);~10. Subjects who taking drugs that reduce tremor, and are not on stable doses of the treatment (ie, had not been taking the medication for a minimum of 30 days), including: gabapentin (note, other such medications may be considered on a case-by-case basis at the discretion of the investigator);~11. Subjects on concurrent immunosuppression with MMD (CellCept) of MPS delayed-release tables (Myfortic), or generic versions of these medication, who have not been on stable doses at least 7 days prior to screening~12. Subjects receiving prednisone or equivalent at a dose \>10 mg per day~13. Either subjects with an episode of acute rejection requiring treatment or subjects with an episode of biopsy-proven or suspected acute rejections that requires treatment within 3 months of screening~14. Subjects who are being actively treated for cancer (with the exception of non-invasive basal cell or squamous cell) or human immunodeficiency virus (HIV)~15. Subjects with any form of current drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LCP-Tacro (Type: EXPERIMENTAL): LCP Tacro tables for once daily oral administration
- Prograf (Type: EXPERIMENTAL): Tacrolimus capsules for twice daily oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete